Cargando…

Comparative Study of Protein Aggregation Arrest by Zwitterionic Polysulfobetaines: Using Contrasting Raft Agents

[Image: see text] Protein aggregation has caused limitations in the study and development of protein-based biopharmaceuticals. We prepared different polysulfobetaine (poly-SPB) polymers via reversible addition fragmentation chain transfer (RAFT) polymerization. These polymers exhibited high efficien...

Descripción completa

Detalles Bibliográficos
Autores principales: Sharma, Neha, Rajan, Robin, Makhaik, Sparsh, Matsumura, Kazuaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2019
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6681992/
https://www.ncbi.nlm.nih.gov/pubmed/31460333
http://dx.doi.org/10.1021/acsomega.9b01409
_version_ 1783441805979680768
author Sharma, Neha
Rajan, Robin
Makhaik, Sparsh
Matsumura, Kazuaki
author_facet Sharma, Neha
Rajan, Robin
Makhaik, Sparsh
Matsumura, Kazuaki
author_sort Sharma, Neha
collection PubMed
description [Image: see text] Protein aggregation has caused limitations in the study and development of protein-based biopharmaceuticals. We prepared different polysulfobetaine (poly-SPB) polymers via reversible addition fragmentation chain transfer (RAFT) polymerization. These polymers exhibited high efficiency in modulation of protein aggregation. We synthesized polysulfobetaines using two different RAFT agents, and analyzed the aggregation profile of lysozyme and insulin. In poly-SPBs, existence of a hydrophobic RAFT agent resulted in visible enhancement of the residual enzymatic activity of lysozyme, whereas it remained unaffected by the hydrophilic RAFT agent. In addition, these polymers resulted in significant suppression in the aggregation of insulin. Increase in the molecular weight of the polymer caused higher efficiency to perpetuate enzymatic activity of lysozyme upon thermal denaturation. The polymers arrested the formation of amyloid like fibrils of lysozyme and insulin, thus indicating their potential to inhibit aggregation. The results unambiguously demonstrate the importance of polysulfobetaine moiety and hydrophobicity in protein aggregation inhibition. This study gives insight into the protein aggregation inhibition by zwitterionic polymers, which have a potential to be developed as aggregation inhibitors in the future.
format Online
Article
Text
id pubmed-6681992
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher American Chemical Society
record_format MEDLINE/PubMed
spelling pubmed-66819922019-08-27 Comparative Study of Protein Aggregation Arrest by Zwitterionic Polysulfobetaines: Using Contrasting Raft Agents Sharma, Neha Rajan, Robin Makhaik, Sparsh Matsumura, Kazuaki ACS Omega [Image: see text] Protein aggregation has caused limitations in the study and development of protein-based biopharmaceuticals. We prepared different polysulfobetaine (poly-SPB) polymers via reversible addition fragmentation chain transfer (RAFT) polymerization. These polymers exhibited high efficiency in modulation of protein aggregation. We synthesized polysulfobetaines using two different RAFT agents, and analyzed the aggregation profile of lysozyme and insulin. In poly-SPBs, existence of a hydrophobic RAFT agent resulted in visible enhancement of the residual enzymatic activity of lysozyme, whereas it remained unaffected by the hydrophilic RAFT agent. In addition, these polymers resulted in significant suppression in the aggregation of insulin. Increase in the molecular weight of the polymer caused higher efficiency to perpetuate enzymatic activity of lysozyme upon thermal denaturation. The polymers arrested the formation of amyloid like fibrils of lysozyme and insulin, thus indicating their potential to inhibit aggregation. The results unambiguously demonstrate the importance of polysulfobetaine moiety and hydrophobicity in protein aggregation inhibition. This study gives insight into the protein aggregation inhibition by zwitterionic polymers, which have a potential to be developed as aggregation inhibitors in the future. American Chemical Society 2019-07-15 /pmc/articles/PMC6681992/ /pubmed/31460333 http://dx.doi.org/10.1021/acsomega.9b01409 Text en Copyright © 2019 American Chemical Society This is an open access article published under a Creative Commons Attribution (CC-BY) License (http://pubs.acs.org/page/policy/authorchoice_ccby_termsofuse.html) , which permits unrestricted use, distribution and reproduction in any medium, provided the author and source are cited.
spellingShingle Sharma, Neha
Rajan, Robin
Makhaik, Sparsh
Matsumura, Kazuaki
Comparative Study of Protein Aggregation Arrest by Zwitterionic Polysulfobetaines: Using Contrasting Raft Agents
title Comparative Study of Protein Aggregation Arrest by Zwitterionic Polysulfobetaines: Using Contrasting Raft Agents
title_full Comparative Study of Protein Aggregation Arrest by Zwitterionic Polysulfobetaines: Using Contrasting Raft Agents
title_fullStr Comparative Study of Protein Aggregation Arrest by Zwitterionic Polysulfobetaines: Using Contrasting Raft Agents
title_full_unstemmed Comparative Study of Protein Aggregation Arrest by Zwitterionic Polysulfobetaines: Using Contrasting Raft Agents
title_short Comparative Study of Protein Aggregation Arrest by Zwitterionic Polysulfobetaines: Using Contrasting Raft Agents
title_sort comparative study of protein aggregation arrest by zwitterionic polysulfobetaines: using contrasting raft agents
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6681992/
https://www.ncbi.nlm.nih.gov/pubmed/31460333
http://dx.doi.org/10.1021/acsomega.9b01409
work_keys_str_mv AT sharmaneha comparativestudyofproteinaggregationarrestbyzwitterionicpolysulfobetainesusingcontrastingraftagents
AT rajanrobin comparativestudyofproteinaggregationarrestbyzwitterionicpolysulfobetainesusingcontrastingraftagents
AT makhaiksparsh comparativestudyofproteinaggregationarrestbyzwitterionicpolysulfobetainesusingcontrastingraftagents
AT matsumurakazuaki comparativestudyofproteinaggregationarrestbyzwitterionicpolysulfobetainesusingcontrastingraftagents